^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD70-targeted CAR-T immunotherapy

    Related drugs:
    9d
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CTX131
    1m
    Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. (PubMed, Oncol Res)
    Although trials for solid tumors (e.g., CYAD-101, CTX130) show modest responses, challenges such as tumor heterogeneity and T cell exhaustion remain. Future research should focus on optimizing gene editing precision, integrating combination therapies, and advancing scalable manufacturing platforms. With expanded targets and cell types, UCAR therapies show promise for both hematologic and solid tumors, reshaping cancer treatment and patient outcomes.
    Review • Journal
    |
    CD52 (CD52 Molecule)
    |
    CYAD-101 • CTX130
    2ms
    Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=15, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions. (PubMed, Transl Oncol)
    CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.
    Review • Journal
    |
    CD70 (CD70 Molecule)
    2ms
    TRAVERSE: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Allogene Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • ALLO-316 • ALLO-647
    3ms
    Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases (clinicaltrials.gov)
    P1, N=11, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    CD70 (CD70 Molecule)
    |
    CD70 CAR-T
    3ms
    Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial (clinicaltrials.gov)
    P1, N=90, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • CD70 CAR-T
    3ms
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Florida | Initiation date: Sep 2025 --> Mar 2025
    Trial initiation date
    |
    8R-70CAR T
    3ms
    Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS (clinicaltrials.gov)
    P1, N=18, Recruiting, The Children's Hospital of Zhejiang University School of Medicine | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    4ms
    RESOLUTION: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (clinicaltrials.gov)
    P1, N=54, Recruiting, Allogene Therapeutics
    New P1 trial
    |
    cyclophosphamide
    5ms
    ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies. (PubMed, J Immunother Cancer)
    These results demonstrate the robust potency and capacity of ADI-270 to extend antitumor activity to cancers with heterogeneous antigen expression. The functional armoring incorporated into ADI-270 provides a mechanism to overcome the limitations of reduced efficacy and persistence within the TME. ADI-270 has the potential to target multiple CD70+ cancers with initial clinical evaluation proceeding in relapsed/refractory clear cell renal cell carcinoma.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    6ms
    A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Weijia Fang, MD | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2024 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide • fludarabine IV • CD70 CAR-T